GeoVax Labs, Inc. announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company's Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, MD, United States, where he held a variety of leadership positions in virology, immunology, preventive medicine, and clinical research and development with the U.S. Army, retiring as a Colonel in 2001.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.682 USD | +3.21% | -1.04% | -68.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.93% | 3.76M | |
+43.49% | 54.04B | |
+43.57% | 41.96B | |
-1.32% | 41.92B | |
-7.59% | 28.35B | |
+12.12% | 26.35B | |
-22.18% | 19B | |
+7.40% | 13B | |
+29.09% | 12.28B | |
+25.52% | 12.19B |
- Stock Market
- Equities
- GOVX Stock
- News GeoVax Labs, Inc.
- GeoVax Labs, Inc Appoints Kelly Mckee as Chief Medical Officer